STOCKHOLM, Sweden, Feb. 07, 2005 (PRIMEZONE) -- The following people have been appointed as members of Vitrolife's nominations committee for the Annual General Meeting in 2005:
Carl Rosen, representing Andra AP-fonden (Second National Pension Insurance Fund) Gunnar Lindberg, representing Lansforsakringars Smabolagsfond Patrik Tigerschiold, representing Skanditek Industriforvaltning
Questions should be addressed to:
Patrik Tigerschiold
Chairman of the Board
Phone +46 8 614 00 20
Magnus Nilsson, CEO
Phone +46 31 721 80 00
+46 708 22 80 61
Anna Ahlberg, CFO
Phone +46 31 721 80 13
+46 708 22 80 13.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes. Vitrolife today has over 70 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=69859&fn=wkr0001.pdf
-0-